

# Frances R Balkwill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5070949/publications.pdf>

Version: 2024-02-01

57  
papers

22,025  
citations

87843

38  
h-index

143943

57  
g-index

58  
all docs

58  
docs citations

58  
times ranked

33961  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer-related inflammation. <i>Nature</i> , 2008, 454, 436-444.	13.7	9,279
2	Tumour necrosis factor and cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 361-371.	12.8	1,514
3	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
4	Inflammation and cancer: advances and new agents. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 584-596.	12.5	901
5	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
6	Mice deficient in tumor necrosis factor- $\hat{\pm}$ are resistant to skin carcinogenesis. <i>Nature Medicine</i> , 1999, 5, 828-831.	15.2	777
7	Re-educating tumor-associated macrophages by targeting NF- $\hat{\rho}$ B. <i>Journal of Experimental Medicine</i> , 2008, 205, 1261-1268.	4.2	700
8	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	13.9	651
9	Cancer-related inflammation: Common themes and therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2012, 22, 33-40.	4.3	567
10	Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF- $\hat{\rho}$ B and JNK. <i>Journal of Immunology</i> , 2005, 175, 1197-1205.	0.4	393
11	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. <i>Cancer Research</i> , 2002, 62, 5930-8.	0.4	367
12	The chemokine system and cancer. <i>Journal of Pathology</i> , 2012, 226, 148-157.	2.1	355
13	The Inflammatory Cytokine Tumor Necrosis Factor- $\hat{\pm}$ Generates an Autocrine Tumor-Promoting Network in Epithelial Ovarian Cancer Cells. <i>Cancer Research</i> , 2007, 67, 585-592.	0.4	350
14	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6083-6096.	3.2	330
15	Harnessing cytokines and chemokines for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 237-253.	12.5	305
16	B regulatory cells and the tumor-promoting actions of TNF- $\hat{\pm}$ during squamous carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 10662-10667.	3.3	299
17	The tumor-promoting actions of TNF- $\hat{\pm}$ involve TNFR1 and IL-17 in ovarian cancer in mice and humans. <i>Journal of Clinical Investigation</i> , 2009, 119, 3011-3023.	3.9	280
18	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	7.7	255

#	ARTICLE	IF	CITATIONS
19	Tumor Necrosis Factor $\hat{\pm}$ As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. <i>Journal of Clinical Oncology</i> , 2007, 25, 4542-4549.	0.8	225
20	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	3.2	217
21	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2012, 72, 66-75.	0.4	189
22	Interleukin-6 Stimulates Defective Angiogenesis. <i>Cancer Research</i> , 2015, 75, 3098-3107.	0.4	184
23	Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. <i>Journal of Proteome Research</i> , 2017, 16, 3083-3091.	1.8	183
24	Murine CD27 <sup>(<math>\hat{\sim}</math>)</sup> $\hat{V}^{36}$ <sup>(+)</sup> $\hat{I}^{31}$ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3562-70.	3.3	176
25	A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 250-262.	3.2	159
26	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016, 76, 6118-6129.	0.4	145
27	The Inflammatory Cytokine Tumor Necrosis Factor- $\hat{\pm}$ Regulates Chemokine Receptor Expression on Ovarian Cancer Cells. <i>Cancer Research</i> , 2005, 65, 10355-10362.	0.4	138
28	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3025-3036.	3.2	124
29	B regulatory cells in cancer. <i>Trends in Immunology</i> , 2013, 34, 169-173.	2.9	110
30	Cancer associated fibroblast FAK regulates malignant cell metabolism. <i>Nature Communications</i> , 2020, 11, 1290.	5.8	95
31	A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 801-813.	3.9	70
32	Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. <i>Clinical Cancer Research</i> , 2003, 9, 84-92.	3.2	69
33	Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. <i>Acta Neuropathologica Communications</i> , 2019, 7, 172.	2.4	65
34	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 5706-5719.	0.4	64
35	Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. <i>Cell Reports</i> , 2020, 30, 525-540.e7.	2.9	61
36	Human T-Lymphotropic Virus Type 1-Induced CC Chemokine Ligand 22 Maintains a High Frequency of Functional FoxP3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2010, 185, 183-189.	0.4	60

#	ARTICLE	IF	CITATIONS
37	The peritoneal tumour microenvironment of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012, 227, 136-145.	2.1	54
38	Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. <i>Journal of Pathology</i> , 2014, 232, 43-56.	2.1	54
39	Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 1255-1264.	0.4	39
40	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
41	Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. <i>Endocrine-Related Cancer</i> , 2019, 26, 853-865.	1.6	35
42	Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2020, 80, 4946-4959.	0.4	34
43	Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 665-681.	1.6	31
44	A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion. <i>IScience</i> , 2021, 24, 102676.	1.9	28
45	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1803-1810.	2.9	23
46	Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. <i>FASEB Journal</i> , 2013, 27, 4244-4253.	0.2	21
47	Modelling TGF $\beta$ 2R and Hh pathway regulation of prognostic matrix molecules in ovarian cancer. <i>IScience</i> , 2021, 24, 102674.	1.9	16
48	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNF $\alpha$ , and IL-1 $\beta$ . <i>Cancer Discovery</i> , 2022, 12, 2140-2157.	7.7	16
49	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 15648-15661.	0.8	13
50	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. <i>Cancers</i> , 2021, 13, 5998.	1.7	8
51	Interest and learning in informal science learning sites: Differences in experiences with different types of educators. <i>PLoS ONE</i> , 2020, 15, e0236279.	1.1	7
52	Loss of mTORC2-induced metabolic reprogramming in monocytes uncouples migration and maturation from production of proinflammatory mediators. <i>Journal of Leukocyte Biology</i> , 2022, 111, 967-980.	1.5	7
53	Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1030-1043.	1.9	6
54	Airway dendritic cell maturation in children exposed to air pollution. <i>PLoS ONE</i> , 2020, 15, e0232040.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Centre of the Cell: Science Comes to Life. PLoS Biology, 2015, 13, e1002240.	2.6	4
56	Mets and NETs: The Awakening Force. Immunity, 2018, 49, 798-800.	6.6	3
57	Cells are Us – combining research and public engagement. Nature Reviews Cancer, 2021, 21, 277-278.	12.8	3